ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…
Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability; Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods ROCHESTER, N.Y., June 25, 2021—Neuroscience company…
Cognivue, Inc. and the American Institute of Balance Announce Inaugural Thought Leader Summit June 25-26, 2021 Audiology and otolaryngology leaders will discuss the industry’s role as part of a standard of care…
Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee The Alliance seeks to transform and improve the complex health and long-term care systems for individuals at risk for and…
VICTOR, N.Y. (WROC)- April 27th, 2021: Top Stories
First FDA-cleared computerized test of cognitive function will be evaluated in the Bio-Hermes study; seeks to improve identification and screening…
Dr. Fred Ma addresses the COVID-19 pandemic and the role of cognitive testing. Cognivue CMO Newsletter, Fall 2020
Cognivue, Inc. has named Fred Ma, MD, PhD, as it’s Chief Medical Officer and Senior Vice President, effective immediately. His nearly four-decade career spans global medical device and pharmaceutical development and commercialization,…
We are excited to announce that Cognivue’s peer-reviewed article, “Validity, reliability and psychometric properties of a computerized cognitive assessment” was published in the World Journal of Psychiatry (WJP). Cognivue is an important…
Cognivue announces the appointment of two key leaders. Joining the company are Dr. Reina Benabou, MD, PhD, as Senior Vice President and Chief Medical Officer and Whitney Parachek as Vice President of…
